Blood Screening Market is expected to foresee significant growth. North America leads the Market Share!

Blood Screening Market is expected to grow at a CAGR of around 10% during the forecast period 2021-2027. Blood screening alludes to various tests completed on blood tests for analysis of a few infections like tuberculosis, HIV, hepatitis, syphilis, and other clinical conditions like flu, pregnancy. It assists with checking illnesses and forestall medical problems and an assortment of different conditions like contaminations and malignant growth.

The driving factor that fuels the market of the blood screening market is incremental growth in the infectious & chronic illnesses, ascend in number of blood donors, awareness about medical care, and growing demand of nucleic acid amplification test (NAT). Besides, government support, expansion in medical services consumption, and technological advancements in the blood screening products & technology have also energized the market growth. On the other hand, factors like stringent administrative policy, shortage of blood donor, and high expenses tests are likely to obstruct the market growth.

For a detailed analysis of the market drivers browse through – https://univdatos.com/report/blood-screening-market/

The COVID-19 pandemic has had a beneficial and bad impact on the blood screening business. Many firms developed different serological assays to identify COVID-19 antibodies in the aftermath of the COVID-19 outbreak. For instance, the United States Food and Drug Administration (FDA) has given Emergency Use Authorization (EUA) to a few serological tests that detect COVID-19 antibodies. In addition, the US Food and Drug Administration (FDA) granted an emergency use authorization (EUA) for the convalescent plasma treatment of COVID-19 for the hospitalized patients. The plasma of COVID-19 recovered patients can be collected and used to treat additional patients with COVID-19. The need for plasma treatment is increasing during days, as is the amount of plasma donations received around the world. Various infectious illnesses and blood typing tests must be performed on all donated plasma. As a result, this component is likely to have a favorable effect on blood screening market. However, the decrease in the number hospital visits and blood donations and blood transfusion-related screenings due to the lockdown and restrictions imposed during the pandemic have hit the market growth.

For a detailed analysis of the Covid-19 Impact on the market browse through – https://univdatos.com/report/blood-screening-market/

Based on product, the market is segmented into Reagents & Kits, Instruments, Software & Services. The reagents & kits segment commanded the largest share of the blood screening market in 2020. Based on Technology, the market is segmented into Nucleic Acid Amplification (NAAT), Enzyme Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blotting, Next Generation Sequencing (NGS). Nucleic Acid Amplification (NAAT) segment dominated the blood screening market in 2020. Based on end user, the market is segmented into Hospitals, Blood Banks, Others. The blood banks segment holds the significant share of the blood screening market.

For a better understanding of the market of Blood Screening, the market is analyzed based on its worldwide adoption in the countries such as North America (United States, Canada, Rest of North America), Europe (Germany, UK, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Rest of APAC), and Rest of World. The blood screening market was dominated by North America. The growing prevalence of infectious & chronic diseases, rising elderly population, rising healthcare expenditure, need for early disease diagnosis and monitoring, robust healthcare infrastructure, and the growing adoption of advanced blood screening technologies in the region are all factors contributing to North America’s highest share.

Request for Sample of the report browse through – https://univdatos.com/get-a-free-sample-form-php/?product_id=11423

Some of the major players operating in the market include Abbott Laboratories, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson And Company, Thermo Fisher Scientific Inc., bioMerieux, Inc., Grifols, S.A., Danaher Corporation, Boster Biological Technology, Demeditec Diagnostics GmbH, etc. Several M&A’s along with partnerships have been undertaken by these players to boost their presence in different regions

Blood Screening Market Segmentation

Market Insight, by Product

• Reagents & Kits
• Instruments
• Software & Services

Market Insight, by Technology

• Nucleic Acid Amplification (NAAT)
• Enzyme Linked Immunosorbent Assay (ELISA)
• Rapid Tests
• Western Blotting
• Next Generation Sequencing (NGS)

Market Insight, by End User

• Hospitals
• Blood Banks
• Others

Market Insight, by Region

• North America Blood Screening Market
  • United States
  • Canada
  • Rest of North America
• Europe Blood Screening Market
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific Blood Screening Market
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia-Pacific
• Rest of World Blood Screening Market

Company Profiled

• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Becton, Dickinson And Company
• Thermo Fisher Scientific Inc.
• bioMerieux, Inc.
• Grifols, S.A.
• Danaher Corporation
• Boster Biological Technology
• Demeditec Diagnostics GmbH